Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319322968> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4319322968 endingPage "e238" @default.
- W4319322968 startingPage "e238" @default.
- W4319322968 abstract "Purpose: Indirect comparison suggests that androgen receptor targeted agents (ARTA) improve progression free survival and are better tolerated compared to docetaxel in mHSPC [1]. NICE interim guidance during the COVID-19 pandemic allowed the use of ARTA in patients with a new diagnosis of mHSPC instead of docetaxel [2]. In this retrospective observational cohort study, we aimed to assess the use of ARTA as a first line treatment in mHSPC during the COVID-19 pandemic compared to docetaxel pre-COVID-19. The primary endpoint was time to progression (biochemical or radiological). Secondary endpoints included PSA response and adverse event rates. Methods: Patients were identified using the ARIA chemotherapy system as those with mHSPC prescribed first line ARTA between 1 March 2020 and 28 February 2021 compared to patients treated with docetaxel between 1 January 2019 and 31 December 2019. Results: 67 (45 ARTA, 22 docetaxel) eligible patients were identified, with a median overall follow-up of 19 months. The median time to progression was significantly longer in the ARTA group when compared with the docetaxel group (56 weeks versus 48 weeks; P = 0.02). The proportion with a PSA reduction >50% was greater in the ARTA group (97.8% versus 90.9%). The proportion of patients with adverse events leading to dose reduction was lower in the ARTA group (26.7% versus 36.4%) as were the rates of treatment related hospital admission (0% versus 22.7%). Conclusion: These data show that ARTA is better tolerated and associated with a longer progression free survival compared with docetaxel in our patient cohort. These data give further evidence for the efficacy and safety of ARTA and supports their continued use as a first line treatment of mHSPC post-COVID-19 pandemic. References [1] Wang L, Paller C, Hong H, De Felice A, Alexander G, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer. JAMA Oncol 2021;7(3):412. [2] https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. Accessed 20 July 2022." @default.
- W4319322968 created "2023-02-08" @default.
- W4319322968 creator A5002623556 @default.
- W4319322968 creator A5019201593 @default.
- W4319322968 creator A5036525673 @default.
- W4319322968 creator A5051679864 @default.
- W4319322968 date "2023-02-01" @default.
- W4319322968 modified "2023-09-26" @default.
- W4319322968 title "Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19" @default.
- W4319322968 doi "https://doi.org/10.1016/j.clon.2022.11.028" @default.
- W4319322968 hasPublicationYear "2023" @default.
- W4319322968 type Work @default.
- W4319322968 citedByCount "0" @default.
- W4319322968 crossrefType "journal-article" @default.
- W4319322968 hasAuthorship W4319322968A5002623556 @default.
- W4319322968 hasAuthorship W4319322968A5019201593 @default.
- W4319322968 hasAuthorship W4319322968A5036525673 @default.
- W4319322968 hasAuthorship W4319322968A5051679864 @default.
- W4319322968 hasBestOaLocation W43193229681 @default.
- W4319322968 hasConcept C121608353 @default.
- W4319322968 hasConcept C126322002 @default.
- W4319322968 hasConcept C143998085 @default.
- W4319322968 hasConcept C167135981 @default.
- W4319322968 hasConcept C197934379 @default.
- W4319322968 hasConcept C203092338 @default.
- W4319322968 hasConcept C2776551883 @default.
- W4319322968 hasConcept C2779134260 @default.
- W4319322968 hasConcept C2780192828 @default.
- W4319322968 hasConcept C2781190966 @default.
- W4319322968 hasConcept C3008058167 @default.
- W4319322968 hasConcept C524204448 @default.
- W4319322968 hasConcept C535046627 @default.
- W4319322968 hasConcept C61367390 @default.
- W4319322968 hasConcept C71924100 @default.
- W4319322968 hasConceptScore W4319322968C121608353 @default.
- W4319322968 hasConceptScore W4319322968C126322002 @default.
- W4319322968 hasConceptScore W4319322968C143998085 @default.
- W4319322968 hasConceptScore W4319322968C167135981 @default.
- W4319322968 hasConceptScore W4319322968C197934379 @default.
- W4319322968 hasConceptScore W4319322968C203092338 @default.
- W4319322968 hasConceptScore W4319322968C2776551883 @default.
- W4319322968 hasConceptScore W4319322968C2779134260 @default.
- W4319322968 hasConceptScore W4319322968C2780192828 @default.
- W4319322968 hasConceptScore W4319322968C2781190966 @default.
- W4319322968 hasConceptScore W4319322968C3008058167 @default.
- W4319322968 hasConceptScore W4319322968C524204448 @default.
- W4319322968 hasConceptScore W4319322968C535046627 @default.
- W4319322968 hasConceptScore W4319322968C61367390 @default.
- W4319322968 hasConceptScore W4319322968C71924100 @default.
- W4319322968 hasIssue "2" @default.
- W4319322968 hasLocation W43193229681 @default.
- W4319322968 hasLocation W43193229682 @default.
- W4319322968 hasOpenAccess W4319322968 @default.
- W4319322968 hasPrimaryLocation W43193229681 @default.
- W4319322968 hasRelatedWork W1652439388 @default.
- W4319322968 hasRelatedWork W2021751111 @default.
- W4319322968 hasRelatedWork W2135620818 @default.
- W4319322968 hasRelatedWork W2568045406 @default.
- W4319322968 hasRelatedWork W2770702948 @default.
- W4319322968 hasRelatedWork W3023947295 @default.
- W4319322968 hasRelatedWork W3132581442 @default.
- W4319322968 hasRelatedWork W4229076799 @default.
- W4319322968 hasRelatedWork W4233890459 @default.
- W4319322968 hasRelatedWork W4291017293 @default.
- W4319322968 hasVolume "35" @default.
- W4319322968 isParatext "false" @default.
- W4319322968 isRetracted "false" @default.
- W4319322968 workType "article" @default.